Status:

COMPLETED

To Investigate the Effects of AZD1981 on the QT Interval

Lead Sponsor:

AstraZeneca

Conditions:

Asthma

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this research study is to evaluate the effect of AZD1981 on the electrical activity of the heart, in particular when the heart muscle is relaxed during a heart beat cycle. The effect of...

Eligibility Criteria

Inclusion

  • Healthy male volunteers aged 18 to 55 years (inclusive)
  • Subjects must be willing to use barrier methods of contraception during study and for 3 months after last dosing.
  • Be a non-smoker or ex-smoker who has stopped smoking for \>6 months

Exclusion

  • Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment)
  • History of additional risk factors for Torsade de Pointes (eg, heart failure, hypokalemia, personal or family history of arrhythmia or long QT syndrome)

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2011

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT01265641

Start Date

January 1 2011

End Date

April 1 2011

Last Update

June 28 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Researche Site

London, UK, United Kingdom